Sensors glean information from radiofrequency ID chips embedded in labels of contrast bottles
VistaTrak looks like a basic cabinet designed to hold bottles of contrast media. Wall-hung and compact, it seems a practical way to keep these bottles handy for use. But mounted to the side of this cabinet is a touchscreen that hints that VistaTrak may be more than it appears.
Lying in wait beneath its simple exterior are sensors that pick up signals from radiofrequency identification (RFID) chips attached to bottles of contrast. These signals indicate the lot number, expiration date, and other information when each bottle is removed from the cabinet. VistaTrak transmits these data to an inventory management system so managers can track the use of contrast and determine when stocks need to be replenished. It even checks automatically for compliance with dosing protocols.
“VistaTrak allows hospitals to not only track their inventory of contrast agents but to watch for patient safety issues, which are becoming critically important when contrast agents are used in an MR or CT suite,” said Douglas Stefanelli, vice president and general manager of diagnostic imaging for Bayer HealthCare Pharmaceuticals. “It also helps compliance with Joint Commission on Accreditation of Healthcare Organizations standards.”
When linked to an electronic medical record or radiology information system, the high-tech cabinet can flag information that may affect the use of contrast material, such as a patient’s glomerular filtration rate (an indicator of kidney disease) or potential allergic reactions, a cochlear implant, or a pacemaker. The password-protected cabinet further safeguards patients by restricting access to staff who are provided specially designed badges or PIN codes.
Previewed by Bayer at RSNA 2007, VistaTrak is scheduled to begin shipping in mid-2008. Bayer’s MR contrast agent Magnevist will be the first to carry a VistaTrak RFID tag.
The cabinet answers some of the challenges facing providers who are being tasked by federal and state regulators, as well as JCAHO, to reduce medication errors. It addresses them in an automated and cost-effective way, according to Scott Bertetti, Bayer’s associate director of business development for diagnostic imaging, using technnology developed by Mobile Aspects and customized by Bayer and Mobile Aspects specifically for the radiology department.
“We created a small cabinet, because real estate is at a premium in the radiology area,” Bertetti said. “We also changed the interface to fit workflow in the radiology department and to address Joint Commission concerns about the use of contrast.”
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
Abbreviated MRI for Hepatocellular Carcinoma: What a New Meta-Analysis Reveals
January 6th 2025For hepatocellular carcinoma screening, a 19-study meta-analysis found the abbreviated MRI sequencing protocol of T2-weighted MRI, diffusion-weighted imaging (DWI) and hepatobiliary phase (HBP) imaging offered 88 percent sensitivity and 93 percent specificity.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.